Hematology
Paul Richardson, MD
Director in 2001, and led the study and development of several pivotal novel drugs including thalidomide, lenalidomide, bortezomib, pomalidomide, panobinostat; Professor of Medicine at Harvard Medical School in 2012, and then became Clinical Program Leader and Director of Clinical Research in 2014.
Paul Richardson, MD - After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology and stem cell transplant from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the study and development of several pivotal novel drugs including thalidomide, lenalidomide, bortezomib, pomalidomide, panobinostat, daratumumab, elotuzumab, and ix
40+
Years in Practice
Credentials
Board Certifications
- Hematology, 1999
- Internal Medicine, 1997
- Medical Oncology, 1998
Education & Training
- University of London, St. Bartholomew's Medical College (MD)
- Beth Israel Deaconess Medical Center, Internal Medicine (Residency)
- Newcastle General and Freeman Hospitals, Internal Medicine (Residency)
- Royal Marsden Hospital, London, Chief Resident (Residency)
- Baystate Medical Center, Tufts University, Hematology & Oncology (Fellowship)
Peer Recognition
- Castle Connolly — Top Doctor
2012-2026 (15 years)
Clinical Focus
Subspecialties
Conditions & Treatments
Practice Details
Hospital Affiliations
- Dana-Farber Cancer Institute
- South County Health
- Dana-Farber/Brigham and Women's Cancer Center
Experience
40+ years in practice